New from SAG: LiquidMate O Brings Reliable Item-Level RFID to Liquid Injectables
Engineered to overcome liquid interference on small, curved pharmaceutical vials, enabling accurate high-density RFID reads in real hospital and pharmacy workflows while supporting scalable, standards-based traceability.
SAG RFID unveiled LiquidMate O, its debut RFID label and a category-defining advancement in pharmaceutical traceability. Built on an innovative, patent-pending antenna design, LiquidMate O enables reliable item-level RFID tagging of liquid-filled medications under real-world clinical handling conditions.
For more than a decade, liquid interference, curved glass vials, and dense storage environments have constrained RFID adoption in hospital pharmacies, limiting deployment to a narrow subset of injectable products.
LiquidMate O is SAG RFID’s most advanced RFID label to date, engineered and independently validated to deliver consistent performance across a broader range of injectable liquid categories that have historically challenged RFID. Performance was verified by AXIA Lab at Michigan State University using representative liquid formulations and scenario-based test environments aligned to actual clinical workflows.
Addressing a persistent operational challenge
Ineffective tracking of liquid-filled injectable medications drives significant losses through expired inventory, misplaced drugs, and compliance exposure. High-value injectable medications consistently emerge as the most critical targets for RFID adoption, accounting for a disproportionate share of drug spend and carrying elevated clinical and regulatory risk.
Reliable item-level visibility supports better inventory accuracy, fewer exceptions, and stronger traceability at the point of care.
Built for manufacturing-scale source tagging
For pharmaceutical manufacturers, LiquidMate O removes a longstanding barrier to scalable source tagging of injectable vials. Engineered for direct integration into existing labeling and packaging workflows, it enables standards-based, source-applied RFID on liquid-filled glass injectable vials without formulation-specific labels, line-speed disruption, major process changes, or downstream manual tagging.
LiquidMate O product highlights
One label across injectable liquids: Consistent performance across multiple formulations with varying dielectric properties, reducing SKU proliferation and enabling scalable source tagging.
Direct-on-vial for injectables: Validated on industry-standard 10 mL glass vials, using a compact 62 × 20 mm label designed for curved, space-constrained vials.
Proven high-density readability: Independently validated to deliver 100% read performance in dense, multi-vial configurations, supporting 360-degree omnidirectional readability.
Standards-based global interoperability: Aligned with GS1 Tagged Item Performance Protocol (TIPP) and GS1 Tag Data Standards (TDS) to support interoperable traceability across manufacturing, distribution, and point-of-care workflows.
AXIA Lab verified performance: Tested under GS1 TIPP protocols using AXIA Lab field simulations designed to reflect real-world medication handling, storage density, and workflow constraints.
SAG RFID and AXIA Lab collaboration
Advancing pharmaceutical traceability requires more than compliance. It demands real-world validation. AXIA Lab of Michigan State University supports healthcare adoption of RFID by defining, characterizing, and validating RFID performance using GS1 TIPP methodologies.
Through collaboration with AXIA Lab, SAG RFID evaluates LiquidMate O against medication-management conditions that reflect actual clinical handling, dense storage, and workflow constraints, moving beyond controlled laboratory assumptions.